Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.12968/hmed.2011.72.1.49 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prediabetes in a French overseas territory: Clinical Characteristics, Risk Factors, and Implications for type 2 diabetes prevention.
Prev Med Rep
November 2024
INSERM, Centre d'Investigation Clinique - Epidémiologie Clinique (CIC-EC) 1410, CHU de La Réunion, Saint-Pierre, La Réunion, France.
Background: People with prediabetes are at high risk of developing type 2 diabetes (T2D). This study evaluates clinical, sociodemographic characteristics, and Finnish Diabetes Risk Score (FINDRISC) of individuals with prediabetes recruited in primary care by their general practitioner (GP) for PREDIABRUN study.
Methods: PREDIABRUN, a prospective cohort study in primary care on Reunion Island, aimed to identify risk factors for developing T2D in 500 adults with prediabetes (18-70 years) between July 2019 and December 2022.
Rationale and Design of the COPERNIC Trial: A Study of On-treatment ctDNA Changes in Chemo-refractory Colorectal Cancer Patients.
Clin Colorectal Cancer
September 2024
Service d'Oncologie Digestive, Université libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (HUB), Institut Jules Bordet, Brussels, Belgium. Electronic address:
Background: Evidence suggests that ctDNA may be a reliable biomarker to monitor metastatic colorectal cancer (CRC) evolution. Nevertheless, evidence on the potential of liquid biopsy in this setting is still low quality, mostly consisting of retrospective studies.
Methods: COPERNIC is an international, multicenter clinical trial.
Immune-Cell-Derived Exosomes as a Potential Novel Tool to Investigate Immune Responsiveness in SCLC Patients: A Proof-of-Concept Study.
Cancers (Basel)
September 2024
Department of Translational Medical Sciences, University of Campania Luigi Vanvitelli, 80131 Naples, Italy.
Article Synopsis
- Small cell lung cancer (SCLC) is a fast-growing lung cancer type that responds well to certain treatments, but not all patients benefit, highlighting a need for new therapies and biomarkers.
- The study investigated how exosomes from the blood of SCLC patients can influence responses to chemoimmunotherapy by examining immune and tumor markers.
- Results showed that exosomes from patients who responded well to treatment significantly increased cancer cell death in lab tests, suggesting they could help understand the interaction between cancer and the immune system.
Trends in sex differences in neurodevelopmental outcomes among extremely preterm infants.
Arch Dis Child Fetal Neonatal Ed
September 2024
Department of Pediatrics, Division of Neonatal and Developmental Medicine, Stanford University School of Medicine and Lucile Packard Children's Hospital, Palo Alto, California, USA.
Objective: To examine whether changes in survival without moderate or severe neurodevelopmental impairment (NDI) at 18-26 months' corrected age from 1999 to 2018 differed between male and female infants.
Design: This retrospective cohort study used data from the NICHD Neonatal Research Network hospitals. Robust Poisson regression models were used to estimate adjusted relative risks (aRRs) and 95% CIs for survival without moderate or severe NDI between males and females.
Overexpression of CCL-20 and CXCL-8 genes enhances tumor escape and resistance to cemiplimab, a programmed cell death protein-1 (PD-1) inhibitor, in patients with locally advanced and metastatic cutaneous squamous cell carcinoma.
Oncoimmunology
August 2024
Medical Oncology Unit, Department of Precision Medicine, Università della Campania "Luigi Vanvitelli", Naples, Italy.
Cemiplimab has demonstrated relevant clinical activity in cutaneous squamous cell carcinoma (cSCC) but mechanisms of primary and acquired resistance to immunotherapy are still unknown. We collected clinical data from locally advanced and/or metastatic cSSC patients treated with cemiplimab in two Italian University centers. In addition, gene expression analysis by using Nanostring Technologies platform to evaluate 770 cancer- and immune-related genes on 20 tumor tissue samples (9 responders and 11 non-responders to cemiplimab) was performed.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!